@article{fdi:010072485,
  title = {{A} systematic approach to the development of a safe live attenuated {Z}ika vaccine},
  author = {{S}en {K}wek, {S}. and {W}atanabe, {S}. and {C}han, {K}. {R}. and {O}ng, {E}. {Z}. and {T}an, {H}. {C}. and {N}g, {W}. {C}. and {N}guyen, {M}. {T}. {X}. and {G}an, {E}. {S}. and {Z}hang, {S}. {L}. and {C}han, {K}. {W}. {K}. and {T}an, {J}. {H}. and {S}essions, {O}. {M}. and {M}anuel, {M}. and {P}ompon, {J}ulien and {C}hua, {C}. and {H}azirah, {S}. and {T}ryggvason, {K}. and {V}asudevan, {S}. {G}. and {O}oi, {E}. {E}.},
  editor = {},
  language = {{ENG}},
  abstract = {{Z}ika virus ({ZIKV}) is a flavivirus that can cause congenital disease and requires development of an effective long-term preventative strategy. {A} replicative {ZIKV} vaccine with properties similar to the yellow fever 17{D} ({YF}17{D}) live-attenuated vaccine ({LAV}) would be advantageous, as a single dose of {YF}17{D} produces lifelong immunity. {H}owever, a replicative {ZIKV} vaccine must also be safe from causing persistent organ infections. {H}ere we report an approach to {ZIKV} {LAV} development. {W}e identify a {ZIKV} variant that produces small plaques due to interferon ({IFN})-restricted viral propagation and displays attenuated infection of endothelial cells. {W}e show that these properties collectively reduce the risk of organ infections and vertical transmission in a mouse model but remain sufficiently immunogenic to prevent wild-type {ZIKV} infection. {O}ur findings suggest a strategy for the development of a safe but efficacious {ZIKV} {LAV}.},
  keywords = {},
  booktitle = {},
  journal = {{N}ature {C}ommunications},
  volume = {9},
  numero = {},
  pages = {art. 1031 [13 p.]},
  ISSN = {2041-1723},
  year = {2018},
  DOI = {10.1038/s41467-018-03337-2},
  URL = {https://www.documentation.ird.fr/hor/fdi:010072485},
}